AstraZenecaUS

Today, we begin trading on the @NYSE. This landmark moment makes it easier for investors to participate in our future and our ambitions to deliver innovative medicines to patients. spr.ly/6015hGnw5 #AZN #NYSE

Rick R. Suarez is appointed Senior Vice President, US President and Head of US BioPharmaceuticals. He will lead the execution of our $50B US R&D and manufacturing investment and the Company’s US BioPharmaceuticals organization. Learn more: spr.ly/6016CUYvK

#News With @GovWesMoore, we announced plans to invest $2 billion to expand our manufacturing footprint in Maryland, part of our $50 billion investment in the US. This will support 2,600 jobs & accelerate access to innovative therapies. spr.ly/60177m7vW

#News We're establishing a landmark partnership with the Commonwealth of Virginia, Eli Lilly, Merck and Virginia’s higher education institutions to create the largest workforce development hub in the US for advanced pharmaceutical manufacturing: spr.ly/60177HpGt

Today, the FDA approved a new treatment option for chronic rhinosinusitis with nasal polyps (CRSwNP), offering patients an alternative way to help address their symptoms. Read the full announcement: spr.ly/6014ANDdw

#News Today we announced our plans to invest $4.5 billion in a new manufacturing facility in Virginia. This includes a proposed $500m increase to support enhanced manufacturing capability, driving life sciences innovation and economic growth: spr.ly/6012As4Qw

Today, with @DaiichiSankyoUS, we announced high-level results from the TROPION-Breast02 Phase III trial of our TROP2-directed antibody drug conjugate for 1st-line metastatic triple-negative #breastcancer. Learn more about these data: bit.ly/46NnvoR #AZUS

The FDA has approved a supplemental new drug application for an asthma rescue medication, which now includes clinically meaningful evidence in patients with mild asthma. Discover the implications this announcement has for asthma patients. astrazeneca-us.com/media/press-re…

We’re proud to share promising phase III trial results highlighting our progress toward remission-driven lupus care. Learn more about the high-level trial results: bit.ly/46pINXQ

Today, we’ve launched a new way to access our FDA-approved influenza vaccine, helping Americans stay protected during the flu season. Millions get the flu each year, yet vaccination rates continue to decline. Learn more: spr.ly/6011fS2hH

Today, in collaboration with @DaiichiSankyoUS we announced the @US_FDA approval of our treatment for adults with previously treated locally advanced or metastatic EGFR-mutated non-small cell #lungcancer #NSCLC. Learn more: bit.ly/4kPwv12 #AZUS

Traditional approaches to asthma rescue may leave people with asthma at risk of exacerbations. Learn more about our latest data, published in @NEJM: bit.ly/4koEotJ #ATS2025

Today, with @DaiichiSankyoUS, we announced high-level results from our DESTINY-Breast11 Phase III trial for HER2-positive early #breastcancer in the neoadjuvant setting. Learn more about the data and its potential impact for patients: spr.ly/6012NGojr #AZUS

Yesterday, we joined @AstraZenecaUS to celebrate a $300 million investment in their new cell therapy facility in Montgomery County —bringing 150 high-skilled jobs & new hope in the fight against cancer. It was great to be joined by the entire District 15 team Senator @BrianJFeldman , Delegates @fraserfor15 , @LilyQiMaryland & Linda Foley, along with Senator Malcolm Augustine, @MontCoExec Marc Elrich & Rockville Mayor Monique Ashton—as well as Secretaries Harry Coker and Sanjay Rai from the Moore-Miller administration.

Millions of people in the U.S. have dyslipidemia. These patients are often left uncontrolled by statin-only treatments, which can lead to cardiovascular events. We’re developing therapies to shape the future of care. Learn more: spr.ly/6010FrqR4 #ACC25

We’re targeting the root causes of inflammation in chronic respiratory diseases such as asthma, COPD and chronic rhinosinusitis with nasal polyps to transform care and patient outcomes. Learn more about our latest trial results in CRSwNP: spr.ly/6019LYNdf #AAAAI25

The impacts of cardiovascular, renal and metabolic (CVRM) diseases on people continue to grow but may go under-recognized. We’re determined to demonstrate the impact of these diseases. Learn more: spr.ly/6011Ih5iz #HeartMonth

Better understanding the risk factors for high blood pressure (hypertension) may help improve outcomes. A lesser-known driver is aldosterone dysregulation. Aldosterone is a hormone that helps regulate blood pressure. #HeartMonth spr.ly/6011Ih5KJ

Today, alongside @DaiichiSankyoUS, we announced the @US_FDA approval of a new indication for our therapy, now available for certain patients with previously treated metastatic #breastcancer. Learn more: spr.ly/6014xTItA #AZUS

Today, in collaboration with @DaiichiSankyoUS, we announced the @US_FDA approval of our new treatment for adults with previously treated advanced HR-positive, HER2-negative #breastcancer. Learn more: spr.ly/6016acm3K #AZUS